20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
New data supporting neurotrophic factor as a potential treatment for Parkinson’s
An article in the Journal of the International Movement Disorders Society reports on some pre-clinical (laboratory) data supporting the development of ‘Glial cell line-Derived Neurotrophic Factor’ (GDNF) as a potential disease-modifying treatment for Parkinson’s.
Jon Goodwin is an astronaut, and has Parkinson’s
In the first private astronaut mission of its kind, Jon Goodwin was a member of the passenger crew on board Virgin Galactic’s VSS Unity. Jon was diagnosed with Parkinson’s in 2014 and, now aged 80, was the second person with the condition to fly to…
The 2023 International Linked Clinical Trials meeting
In June, Cure Parkinson’s gathered 23 of the world’s leading Parkinson’s experts together for the annual International Linked Clinical Trials (iLCT) meeting. The iLCT committee was created in 2012 through a collaboration between Cure Parkinson’s and Van Andel Institute with the goal of prioritising potential…
Positive phase 1 results for BlueRock
BlueRock Therapeutics has reported positive results from the phase 1 trial of its cell-replacement therapy for Parkinson’s
World Parkinson’s Congress 2023
There is no other meeting in the Parkinson’s space that is quite like the World Parkinson Congress! Hosted for the first time in 2004, the World Parkinson Congress (WPC) is an inclusive international Parkinson’s meeting that draws delegates from around the globe representing a broad…